DE69931279D1 - Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma - Google Patents

Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma

Info

Publication number
DE69931279D1
DE69931279D1 DE69931279T DE69931279T DE69931279D1 DE 69931279 D1 DE69931279 D1 DE 69931279D1 DE 69931279 T DE69931279 T DE 69931279T DE 69931279 T DE69931279 T DE 69931279T DE 69931279 D1 DE69931279 D1 DE 69931279D1
Authority
DE
Germany
Prior art keywords
ldl
lipoprotein
cholesterol
vldl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931279T
Other languages
English (en)
Other versions
DE69931279T2 (de
Inventor
M Medford
Uday Saxena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atherogenics Inc
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Publication of DE69931279D1 publication Critical patent/DE69931279D1/de
Application granted granted Critical
Publication of DE69931279T2 publication Critical patent/DE69931279T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69931279T 1998-11-09 1999-11-09 Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma Expired - Lifetime DE69931279T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10764498P 1998-11-09 1998-11-09
US107644P 1998-11-09
PCT/US1999/026519 WO2000028332A1 (en) 1998-11-09 1999-11-09 Methods and compositions to lower plasma cholesterol levels

Publications (2)

Publication Number Publication Date
DE69931279D1 true DE69931279D1 (de) 2006-06-14
DE69931279T2 DE69931279T2 (de) 2007-04-12

Family

ID=22317677

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931279T Expired - Lifetime DE69931279T2 (de) 1998-11-09 1999-11-09 Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma

Country Status (10)

Country Link
EP (1) EP1137948B1 (de)
JP (1) JP2002529740A (de)
CN (1) CN1332849A (de)
AT (1) ATE326014T1 (de)
AU (1) AU1911200A (de)
CA (1) CA2350316A1 (de)
DE (1) DE69931279T2 (de)
IL (2) IL143057A0 (de)
MX (1) MXPA01004683A (de)
WO (1) WO2000028332A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009370B1 (ru) 1997-05-14 2007-12-28 Атеродженикс, Инк. Соединение и фармацевтическая композиция для ингибирования экспрессии vcam-1
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
WO2001025193A1 (fr) * 1999-10-04 2001-04-12 Nippon Soda Co., Ltd. Composes phenoliques et supports d'enregistrement les contenant
CA2403823A1 (en) * 2000-03-21 2001-09-27 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of vcam-1
WO2001077072A2 (en) * 2000-04-11 2001-10-18 Atherogenics, Inc. Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
ITMI20020597A1 (it) * 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
US7294737B2 (en) 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
WO2008118948A1 (en) 2007-03-26 2008-10-02 Atherogenics, Inc. Methods and compositions of derivatives of probucol for the treatment of diabetes
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
EP2443458A4 (de) * 2009-06-17 2012-12-26 Maine Standards Company Llc Verfahren zur messung lipoproteinspezifischer apolipoproteine
WO2016187250A1 (en) * 2015-05-19 2016-11-24 La Jolla Institute For Allergy And Immunology Human apob100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
WO2018045015A1 (en) * 2016-09-01 2018-03-08 Kevin Jon Williams Methods and kits for reducing the susceptibility of lipoprotein particles to atherogenic aggregation induced by arterial-wall enzymes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
DE69434198T2 (de) * 1993-12-10 2005-12-29 Merrell Pharmaceuticals Inc., Cincinnati Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl-phenol derivaten
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
CH691957A5 (de) * 1996-09-03 2001-12-14 Urs Tschudin Schleifmaschine.

Also Published As

Publication number Publication date
CA2350316A1 (en) 2000-05-18
EP1137948A1 (de) 2001-10-04
CN1332849A (zh) 2002-01-23
WO2000028332A9 (en) 2000-09-28
EP1137948B1 (de) 2006-05-10
MXPA01004683A (es) 2002-09-18
WO2000028332A1 (en) 2000-05-18
AU1911200A (en) 2000-05-29
ATE326014T1 (de) 2006-06-15
IL143057A0 (en) 2002-04-21
JP2002529740A (ja) 2002-09-10
DE69931279T2 (de) 2007-04-12
IL143057A (en) 2010-04-15

Similar Documents

Publication Publication Date Title
DE69931279D1 (de) Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma
Roberts et al. A cell-based model of thrombin generation
Oka et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive
Morton et al. Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk
Marais et al. Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E
Barrans et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases
Gaubatz et al. Isolation and characterization of the two major apoproteins in human lipoprotein [a].
ZA200107598B (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein Al, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol.
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
EP1155121A4 (de) Zusammensetzungen und verfahren zur regulierung des serumcholesterins
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
Benitez-Amaro et al. Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation
Soutar et al. The characterization of lipoproteins in the high density fraction obtained from patients with familial lecithin: cholesterol acyltransferase deficiency and their interaction with cultured human fibroblasts.
IL160533A0 (en) Methods of screening molecules that are used to prevent cardiovascular diseases
Mendez et al. Limited proteolysis of high density lipoprotein abolishes its interaction with cell-surface binding sites that promote cholesterol efflux
Trezzi et al. Subfractionation of human very low density lipoproteins by heparin-Sepharose affinity chromatography
DK0896629T3 (da) Fremgangsmåder og præparater til påvisning af splejsningsdefekter i dihydropyrimidindehydro-genasegenet
Minnich et al. Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3'(Arg136–> His): association with mild dyslipidemia and double pre-beta very low density lipoproteins
Dresel et al. A simple and rapid anti-ligand enzyme immunoassay for visualization of low-density lipoprotein membrane receptors
London et al. Zymogen factor IX potentiates factor IXa-catalyzed factor X activation
Dhananjaya et al. Evidence for existence of venom 5′ nucleotidase in multiple forms through inhibition of concanavalin A
Adolph Cell cycle variations in ADP-ribosylation of HeLa nuclear proteins
DE69826717D1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition